Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07138898 · ClinicalTrials.gov registry record · Phase 2
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
A Phase 2 study, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT07138898: Recruiting Phase 2 study, sponsored by NYU Langone Health.
NCT07138898 is a Phase 2 study that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07138898, a Phase 2 study, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.
Interventions
- DRUG Methotrexate
- DRUG Azathioprine
- DRUG Leflunomide
- DRUG Hydroxychloroquine
- DRUG Sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT07138898 shows while recruiting
NCT07138898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 5 interventions - of which Methotrexate is the first listed.
NCT07138898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07138898 about?
NCT07138898 is a clinical study titled "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty". The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, compar...
What is the current status of trial NCT07138898?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-12. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07138898?
The interventions under investigation include: Methotrexate (DRUG), Azathioprine (DRUG), Leflunomide (DRUG), Hydroxychloroquine (DRUG), Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT07138898?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07138898's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI